Evoke Pharma, Inc. (EVOK): Price and Financial Metrics
EVOK Price/Volume Stats
| Current price | $0.48 | 52-week high | $2.42 |
| Prev. close | $0.55 | 52-week low | $0.42 |
| Day low | $0.48 | Volume | 20,940 |
| Day high | $0.57 | Avg. volume | 56,782 |
| 50-day MA | $0.62 | Dividend yield | N/A |
| 200-day MA | $1.07 | Market Cap | 4.06M |
EVOK Stock Price Chart Interactive Chart >
Evoke Pharma, Inc. (EVOK) Company Bio
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.
Latest EVOK News From Around the Web
Below are the latest news stories about EVOKE PHARMA INC that investors may wish to consider to help them evaluate EVOK as an investment opportunity.
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal sprayEvoke Pharma CEO Dave Gonyer joined Steve Darling from Proactive to share news the company has achieved a significant milestone with the listing of its recently issued U.S. patent related to GIMOTI... |
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI PatentGIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Th |
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTIThe Company Will Submit for FDA Orange-Book Listing in the Near TermSOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s com |
Evoke Pharma Reports Third Quarter 2023 Financial Results38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDA |
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide Image 1 All-Cause HCRU visits in 6-month post-index period for NMCP and OMCP patients Image 2 All-Cause HRCU Costs between NMCP and OMCP patients over 6-month post index period SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: |
EVOK Price Returns
| 1-mo | -21.18% |
| 3-mo | -37.66% |
| 6-mo | -63.22% |
| 1-year | -77.14% |
| 3-year | -97.56% |
| 5-year | -94.50% |
| YTD | -54.30% |
| 2023 | -60.81% |
| 2022 | -59.39% |
| 2021 | -78.68% |
| 2020 | 59.26% |
| 2019 | -34.68% |
Loading social stream, please wait...